BIOMAT Database Logo BIOMAT Database Logo

Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/beta-thalassaemia. 2006

A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos

UI MeSH Term Description Entries
D008297 Male Males
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D017086 beta-Thalassemia A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent. Anemia, Cooley's,Anemia, Erythroblastic,Anemia, Mediterranean,Hemoglobin F Disease,Thalassemia Major,Thalassemia Minor,Erythroblastic Anemia,Mediterranean Anemia,Microcytemia, beta Type,Thalassemia Intermedia,Thalassemia Major (beta-Thalassemia Major),Thalassemia Minor (beta-Thalassemia Minor),Thalassemia, beta Type,beta Thalassemia,Anemia, Cooley,Anemia, Cooleys,Anemias, Erythroblastic,Anemias, Mediterranean,Cooley's Anemia,Disease, Hemoglobin F,Intermedia, Thalassemia,Intermedias, Thalassemia,Major, Thalassemia (beta-Thalassemia Major),Majors, Thalassemia (beta-Thalassemia Major),Mediterranean Anemias,Microcytemias, beta Type,Minor, Thalassemia (beta-Thalassemia Minor),Minors, Thalassemia (beta-Thalassemia Minor),Thalassemia Intermedias,Thalassemia Major (beta Thalassemia Major),Thalassemia Majors (beta-Thalassemia Major),Thalassemia Minor (beta Thalassemia Minor),Thalassemia Minors (beta-Thalassemia Minor),Thalassemia, beta,Thalassemias, beta,Thalassemias, beta Type,Type Microcytemia, beta,Type Microcytemias, beta,Type Thalassemia, beta,Type Thalassemias, beta,beta Thalassemias,beta Type Microcytemia,beta Type Microcytemias,beta Type Thalassemia,beta Type Thalassemias
D018396 Mucin-1 Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer. Antigen CA-15-3,CA-15-3 Antigen,Episialin,Epithelial Membrane Antigen,Epithelial Mucin, Polymorphic,Muc1 Mucin,Polymorphic Epithelial Mucin,Antigens, CD227,CA 15-3 Antigen,CA 15.3 Antigen,CD227 Antigen,Antigen CA 15 3,Antigen, CA 15-3,Antigen, CA 15.3,Antigen, CA-15-3,Antigen, CD227,Antigen, Epithelial Membrane,CA 15 3 Antigen,CA-15-3, Antigen,CD227 Antigens,Membrane Antigen, Epithelial,Mucin 1,Mucin, Muc1,Mucin, Polymorphic Epithelial

Related Publications

A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Serum amylase levels in homozygous sickle cell patients.
May 1991, Journal of the National Medical Association,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Comparison of sickle cell-beta0 thalassaemia with homozygous sickle cell disease.
January 1979, British journal of haematology,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Plasma cyclic nucleotide levels in patients with homozygous beta-thalassaemia.
April 1985, Scandinavian journal of haematology,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Serum levels of TAG 72 and CA 15.3 in patients with gynaecological neoplasms.
January 1992, European journal of gynaecological oncology,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer.
January 1989, The International journal of biological markers,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
January 1993, The International journal of biological markers,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Serum zinc and copper levels in sickle cell anaemia and beta-thalassaemia in North Jordan.
December 1995, Annals of tropical paediatrics,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Serum immunoglobulin levels in children with homozygous sickle cell disease.
October 1982, Clinica chimica acta; international journal of clinical chemistry,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Increased IgA natural autoantibody activity in sera of patients with homozygous beta-thalassaemia.
January 1990, Autoimmunity,
A Symeonidis, and A Kouraklis-Symeonidis, and I Constantinidou, and E Solomou, and S Kougelou, and P Vassilakos, and N Zoumbos
Serum immunoglobulin concentrations before and after splenectomy in patients with homozygous beta-thalassaemia.
June 1978, Journal of clinical pathology,
Copied contents to your clipboard!